您现在的位置是:Fxscam News > Foreign News
FDA approves Eli Lilly's new drug for early Alzheimer's treatment.
Fxscam News2025-07-20 21:46:48【Foreign News】4人已围观
简介China Foreign Exchange Network,Foreign exchange rate query,The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly's drug for the treatm
The China Foreign Exchange NetworkU.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly's drug for the treatment of early Alzheimer's disease, making it the second therapy available to American patients that slows the progression of this neurodegenerative disease.
The drug, named Kisunla, was approved based on unanimous recommendations from external FDA experts who believed the benefits for early Alzheimer's patients outweighed the risks.
"This is substantial progress," said Joanne Pike of the Alzheimer's Association. "Having multiple treatment options has been our long-anticipated goal, and this is an important advancement for everyone affected by this challenging and devastating disease."
Like the competing drug Leqembi, approved a year ago by Eisai and Biogen, donanemab works by clearing Alzheimer's-related proteins—beta-amyloid—from the brain.
A key distinction of donanemab is its limited dosing regimen, allowing patients to stop treatment once brain scans no longer show amyloid plaques.
Eli Lilly's drug is priced at $695.65 per vial, or about $32,000 annually, comprising 13 infusions. This is slightly higher than Eisai's Leqembi, which costs $26,500 per year.
BMO analyst Evan Seigerman said this price reflects the fact that patients can discontinue treatment, unlike Leqembi which requires long-term therapy.
Dr. Erik Musiek, a neurologist at Washington University's Barnes-Jewish Hospital, stated, "It's not clear how these details will be applied in clinical practice, but I think it will save significant costs, and patients will prefer this treatment approach."
Risk Warning and DisclaimerThe market carries risks, and investment should be cautious. This article does not constitute personal investment advice and has not taken into account individual users' specific investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular circumstances. Investing based on this is at one's own responsibility.
很赞哦!(2867)
相关文章
- ECB's Nagel: Rate cuts to neutral range should be gradual, warns against excess.
- Oil price fluctuations, OPEC+ meeting becomes the focus
- Disagreements within the EU are hindering the progress of US
- The SEC vs. Ripple lawsuit enters a new phase, intensifying XRP price fluctuations.
- Grain market bullish! Soybeans gain on policy support, wheat leads CBOT futures.
- Korean central bank warns housing price surge may raise debt and risk financial stability
- Cryptocurrency Tycoon SBF's Fate: Sentenced to 25 Years in Prison and a $11 Billion Fine
- Key Mineral Supply Chain Risks Surge
- Expecting a Fed rate cut and ETF boost, Bitcoin hit $65,000 for the first time in three weeks.
- Oil prices fluctuate at high levels as the market focuses on Asian data and Iran nuclear talks.
热门文章
站长推荐
U.S. Treasuries lose appeal as foreign investors may shift to domestic bond markets.
The latest list of scam cryptocurrency exchanges exposed.
Iran signals willingness for talks; oil prices drop 4% as markets react to potential de
Euro at turning point as Germany's CPI hits 2% ECB target,Lagarde warns of inflation volatility
US Dollar Index nears 107 as Fed rates and Trump expectations boost it for five days.
Oil prices fluctuate due to the impact of nuclear negotiations and ceasefire expectations.
Trump supports US
EU Economic Commissioner says progress made in trade talks with the United States